Thalys(SH:603716) Shang Hai Zheng Quan Bao·2025-09-17 19:58Investment Overview - The company plans to increase its investment in Wuhan Huajiyuan Biotechnology Development Co., Ltd. by 42.74 million yuan, raising its ownership from 30% to 41% [2][10] - The actual controller, Mr. Wen Wei, intends to acquire 10% of the shares from shareholder Sun Danping for 27.2 million yuan, with the total investment from both parties amounting to 69.94 million yuan [2][10] Transaction Details - The investment will be used for the clinical trials of a hypertension treatment vaccine project (HJY-ATRQβ-001) [8][19] - The transaction has been approved by the company's board and will be submitted for shareholder approval, with related parties abstaining from voting [3][27] Financial Impact - The investment is expected to support the development of the target company's business and align with the company's strategic transformation and optimization of its business structure [26] - The target company will be included in the company's consolidated financial statements as a controlled subsidiary in 2026 [2][26] Approval Process - The transaction has undergone necessary approvals from the board's independent directors and strategic committee, and it will be presented at the upcoming shareholder meeting [3][27] Risk Considerations - The target company is currently in the clinical stage of product development and has not yet generated profits, leading to uncertainties regarding future revenue and investment returns [4][29] - The investment may have limited short-term impact on the company's main business and cash flow [5][29]